In adult rat ventricular cardiomyocytes, noradrenaline exerts dual effects on protein synthesis: increases via ␣ 1 -adrenoceptors and decreases via ␤ 1 -adrenoceptors. Carvedilol and bucindolol are ␤-blockers with additional ␣ 1 -adrenoceptor blocking activities. We studied the effects of carvedilol and bucindolol on noradrenaline-induced protein synthesis (assessed by [ 
I]iodocyanopindolol and [
3 H]prazosin revealed that carvedilol had a much higher affinity to ␣ 1 -adrenoceptors than bucindolol (␤ 1 -/␣ 1 -adrenoceptor ratio for carvedilol, 1:2.7; for bucindolol, 1:43). Noradrenalineevoked increases in protein synthesis were enhanced by propranolol (1 M) and ␤ 1 -adrenoceptor-selective antagonists bisoprolol (1 M) and CGP 20712A [1-[2-((3-carbamoyl-4-hydroxy)phenoxy)-ethyl-amino]-3-[4-(1-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propranol methanesulfonate] (300 nM). Carvedilol (100 pM-10 M) inhibited 1 M noradrenalineinduced increase in protein synthesis with monophasic concentration-inhibition curves independent of whether CGP 20712A was present or not; K i values for carvedilol were 5 to 6 nM. In contrast, bucindolol (100 pM-10 M) inhibited l M noradrenaline-induced increase in protein synthesis with a bellshaped concentration-inhibition curve; it increased noradrenaline-induced protein synthesis at 10 nM, although at concentrations Ͼ100 nM it was inhibited. In the presence of 300 nM CGP 20712A or 1 M propranolol, however, bucindolol inhibited 1 M noradrenaline-induced increase in protein synthesis with monophasic concentration-inhibition curves; K i values were 40 to 75 nM. On the other hand, both carvedilol and bucindolol inhibited 1 M phenylephrine-induced protein synthesis with monophasic concentration-inhibition curves; K i values were 4 (carvedilol) and 45 nM (bucindolol). These results indicate that, at low (␤-adrenoceptor blocking) concentrations, bucindolol can enhance noradrenaline-induced protein synthesis whereas it is inhibited by carvedilol.
␤-Adrenoceptor antagonists are now commonly used in the treatment of chronic heart failure patients (for review, see Bristow, 2000) . Beneficial effects including reduction of mortality have been demonstrated not only for ␤ 1 -adrenoceptorselective antagonists such as metoprolol (MERIT-HF Study Group, 1999; Hjalmarson and Fagerberg, 2000) or bisoprolol (CIBIS-II Investigators and Committees, 1999) but also for the nonselective ␤-adrenoceptor antagonist carvedilol (CAP-RICORN Investigators, 2001; Packer et al., 2001; Tendera and Ochala, 2001 ). On the other hand, a recent large trial with bucindolol, another nonselective ␤-adrenoceptor antagonist, failed to produce a significant reduction in mortality in patients with chronic heart failure (Bristow, 2000) . Bucindolol (Hershberger et al., 1990) and carvedilol (Bristow et al., 1992) are ␤-adrenoceptor antagonists with a similar affinity at ␤ 1 -and ␤ 2 -adrenoceptors but differ in their affinities at ␣ 1 -adrenoceptors. Carvedilol exhibited about 2-to 3-fold selectivity for ␤ 1 -versus ␣ 1 -adrenoceptors whereas bucindolol was found to have about 60 to 70 times higher affinity at ␤ 1 -versus ␣ 1 -adrenoceptors (Sponer and Feuerstein, 1999; Bristow, 2000) . We have recently shown that, in adult rat ventricular cardiomyocytes, the noradrenaline-induced increase in rate of protein synthesis (a marker of the development of a hypertrophic phenotype) is composed of two components: an ␣ 1 -adrenoceptor mediated increase in rate of protein synthesis, and a ␤ 1 -adrenoceptor mediated reduction in rate of protein synthesis (Schä fer et al., 2001) . The aim of this study was to find out whether the differences in affinities to ␣ 1 -adrenoceptors of carvedilol and bucindolol might lead to differences in their interaction with noradrenalineinduced increase in rate of protein synthesis (assessed by This work was supported by grants from the Deutsche Forschungsgemeinschaft (Bonn, Germany; SFB TR 2-01) and by GlaxoSmithKline Pharmaceuticals (King of Prussia, PA).
[ 3 H]phenylalanine incorporation in the cardiomyocytes) in adult rat ventricular cardiomyocytes.
Materials and Methods
Preparation of Cardiomyocyte Culture of Adult Rats. Left ventricular cardiomyocytes were isolated from 12-week-old male Wistar rats exactly as recently described (Pönicke et al., 2000) . Freshly isolated cardiomyocytes were gently diluted in sterile culture medium M199, pH 7.4, supplemented with 10% newborn calf serum. To study [
3 H]phenylalanine incorporation, the cardiomyocyte suspension was seeded into 12-well plates (16,000 cells per well), which had been coated with 4% fetal calf serum in medium M199 for 24 h at 37°C (in a humidified incubator at 95% air/5% CO 2 ) and incubated for 16 h at 37°C. Thereafter, the cultures were rinsed with serum-free Hanks' balanced salt solution to remove damaged, rounded, and nonattached cells, and the rod-shaped cells were cultured in serum-free medium M199 supplemented with 2 mM Lcarnitine, 5 mM taurine, 5 mM creatine, and antibiotics (100 U ml Ϫ1 penicillin and 100 g ml Ϫ1 streptomycin). To prevent growth of nonmyocytes the culture medium was supplemented with 10 M cytosine-␤-D-arabinofuranoside.
[ 3 H]Phenylalanine Incorporation. Protein synthesis by cardiomyocytes was assessed as incorporation of [ 3 H]phenylalanine into cells as recently described (Pönicke et al., 2000) . Briefly, after addition of [ 3 H]phenylalanine (0.5 Ci ml Ϫ1 ) at 37°C and the addition of various concentrations of noradrenaline or phenylephrine in the presence or absence of the various antagonists, cells were cultured for 16 h at 37°C in 95% air/5% CO 2 . Ascorbate (100 M) was always present in the medium during this incubation period as an antioxidant. Thereafter cells were washed with ice-cold 0.9% NaCl solution to remove attached radioactivity and incubated for 24 h at 4°C with 10% trichloroacetic acid. Acid-insoluble precipitates were washed again with 10% trichloroacetic acid and twice with 0.9% NaCl. The remaining precipitate on the culture dishes was solubilized in 1 N NaOH supplemented with 0.1% sodium dodecyl sulfate at room temperature for 24 h, and incorporation of radioactivity into acidinsoluble cell mass was determined by the use of a liquid scintillation counter (Beckman LS 6000; Beckman Coulter, Inc., Fullerton, CA). We have recently shown that under these experimental conditions (Michel et al., 1987 (Michel et al., 1993 ) was purchased from PerkinElmer Life Sciences (Zaventem, Belgium), (Ϫ)-noradrenaline bitartrate, L-phenylephrine hydrochloride, L-phenylalanine, cytosine-␤-D-arabinofuranoside, sodium dodecyl sulfate, trypsin (crude), L-carnitine, taurine, creatine, propranolol, and ICI 118,551 were purchased from Sigma-Aldrich (Deisenhofen, Germany). CGP 20712A and CGP 12177 was kindly donated by Ciba-Geigy (Basel, Switzerland). Carvedilol and bucindolol hydrochloride were kindly provided by Dr. Eliot H. Ohlstein (GlaxoSmithKline, King of Prussia, PA). Hanks' balanced salt solution, culture medium M199, and penicillin-streptomycin were obtained from Invitrogen (Eggenstein, Germany). All other chemicals were of the highest purity grade commercially available.
Statistical Evaluations. Data given are means Ϯ S.E.M. of n experiments. Experimental data for agonist-induced increases in rate of protein synthesis were analyzed by fitting sigmoidal curves to the experimental data using the GraphPad Prism 3.0 program (GraphPad Software, San Diego, CA); in these calculations the bottom of the curves were fixed to 100% (i.e., no increases in rate of protein synthesis above control), the Hill slopes were fixed 1.0. Antagonist concentration-inhibition curves were also analyzed by the GraphPad Prism 3.0 program. Statistical significance of difference was analyzed by paired two-tailed Student's t test. A p value less than 0.05 was considered to be significant. All statistical calculations were performed with the GraphPad Prism 3.0 program.
Results
Affinities of Carvedilol and Bucindolol at ␣ 1 -and ␤-Adrenoceptors. Carvedilol (10 pM-10 M) and bucindolol (10 pM-10 M) inhibited [
125 I]iodocyanopindolol binding (100 pM) to membranes from rat left ventricle (in the presence of 50 nM ICI 118,551 ϭ homogeneous population of ␤ 1 -adrenoceptors) and from rat lung (in the presence of 300 nM CGP 20712A ϭ homogenous population of ␤ 2 -adrenoceptors) with concentration-inhibition curves that were best described by a one-site fit. From these curves, K i values of 0.7 to 1.0 nM for carvedilol and 1.2 to 1.8 nM for bucindolol were calculated (see Table 1 ). Studies with human cardiac membranes had suggested that binding of carvedilol and bucindolol to ␤-adrenoceptors can be modulated by guanine nucleotides (Hershberger et al., 1990; Bristow et al., 1992; Maack et al., 2000) . In the present study, however, addition of 100 M GTP to the incubation medium did not affect the concentration-inhibition curves of carvedilol or bucindolol, neither at rat ␤ 1 -nor at rat ␤ 2 -adrenoceptors (Table 1), in accordance   TABLE 1 Affinities (nM) of carvedilol and bucindolol at rat heart ␤ 1 -, rat lung ␤ 2 -, and rat liver ␣ 1 -adrenoceptors Affinities (nM) of carvedilol, bucindolol and propranolol were determined from competition curves with [ with recently published data from Willette et al. (1999) . Carvedilol (100 pM-10 M) and bucindolol (100 pM-10 M) inhibited [ 3 H]prazosin binding (1 nM) to rat liver membranes with monophasic concentration-inhibition curves; affinity of carvedilol to rat ␣ 1 -adrenoceptors was, however, about 30 times higher than that of bucindolol (Table 1) .
Effect of Carvedilol and Bucindolol on Noradrenaline-Induced Increase in Rate of Protein Synthesis in Cardiomyocytes of Adult Rats. We have recently shown that noradrenaline (NA, 1 nM-10 M) in adult rat ventricular cardiomyocytes concentration-dependently increases the rate of protein synthesis (assessed as [
3 H]phenylalanine incorporation); this NA effect can be enhanced by the ␤-adrenoceptor antagonists propranolol (nonselective), CGP 20712A and atenolol (␤ 1 -adrenoceptor-selective; Schä fer et al., 2001) . In the present study, NA (1 nM-10 M) concentration-dependently increased [
3 H]phenylalanine incorporation into cardiomyocytes (Fig. 1) , maximal increase amounted to 130 Ϯ 1% of control, pEC 50 value was 6.0 Ϯ 0.2. The ␤ 1 -adrenoceptor antagonist bisoprolol (1 M) led to a significant increase in rate of protein synthesis at each NA concentration (NA Ն 100 nM), maximal increase was 151 Ϯ 5% of control. In addition, the concentration-effect curve for NA was significantly shifted to the left; pEC 50 value in the presence of bisoprolol was 7.2 Ϯ 0.2 (p Ͻ 0.05, Fig. 1 ). Bucindolol (100 pM-10 M) influenced 1 M NA-induced increase in rate of protein synthesis with a bell-shaped concentrationinhibition curve (Fig. 2A) ; at concentrations up to 10 nM, it increased NA-induced protein synthesis whereas at concentrations Ͼ10 nM, NA-induced protein synthesis was inhibited. Addition of 300 nM CGP 20712A to the incubation medium significantly (p Ͻ 0.05) increased 1 M NA-induced protein synthesis from 131 Ϯ 4% to 154 Ϯ 5%; in the presence of CGP 20712A, bucindolol (100 pM-10 M) inhibited NAinduced protein synthesis with a monophasic concentrationinhibition curve and a K i value of 38.4 Ϯ 8.0 nM (n ϭ 9, Fig.  2A) . A monophasic concentration-inhibition curve for bucindolol (K i value 72.5 Ϯ 16 nM, n ϭ 4) was also observed when in the cardiomyocytes ␤-adrenoceptors were antagonized by 1 M propranolol (Fig. 2B) .
We next tested whether bucindolol might have also dual effects on the concentration-response curve for NA-induced protein synthesis. As shown in Fig. 3 , in the presence of the low concentration of 10 nM bucindolol, NA (100 nM-10 M) caused a higher increase in [ 3 H]phenylalanine incorporation at each concentration than in the absence of bucindolol whereas in the relatively high concentration of 1 M bucindolol caused a significant shift to the right of the concentration-response curve of NA; at 10 M NA, the increase in 
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In contrast to bucindolol, carvedilol (100 pM-10 M) inhibited 1 M NA-induced increase in rate of protein synthesis with a monophasic concentration-inhibition curve (Fig.  4A) independent of whether or not ␤ 1 -adrenoceptors were blocked with CGP 20712A (300 nM); K i values for carvedilol were 5.0 Ϯ 1.3 nM (n ϭ 7) in the absence and 5.7 Ϯ 1.4 nM (n ϭ 7) in the presence of 300 nM CGP 20712A. Accordingly, carvedilol did not exert a dual effect on the concentrationresponse curve for NA-induced protein synthesis; the low (10 nM) concentration of carvedilol was without effect whereas the higher (100 nM and 1 M) concentrations of carvedilol shifted the concentration-response curve for NA to the right to higher concentrations (Fig. 4B) .
Effects of Carvedilol and Bucindolol on Phenylephrine-Induced Increase in Rate of Protein Synthesis. In a final set of experiments, we studied the effects of carvedilol and bucindolol on phenylephrine (PE)-induced increase in rate of protein synthesis because PE is an ␣ 1 -adrenoceptor agonist that exerts ␤-adrenoceptor agonist activity only in concentrations Ͼ1 M. PE (1 M) increased protein synthesis in the adult rat cardiomyocytes to 150 Ϯ 3% (Fig. 5, A and B, n ϭ 20), i.e., a value in a range similar to that induced by 1 M NA in the presence of CGP 20712A in the same cardiomyocytes preparations (cf. Figs. 2A and 4A) ; 300 nM CGP 20712A did not affect the increase in protein synthesis induced by 1 M PE [maximal increase in the presence of CGP 20712A was 148 Ϯ 10% (n ϭ 4, Fig. 5A ), respectively, 153 Ϯ 6% (n ϭ 4, Fig. 5B) ]. Both bucindolol and carvedilol inhibited 1 M PE-induced protein synthesis with monophasic concentration-inhibition curves; K i values were 44.7 Ϯ 6.3 nM (n ϭ 10) for bucindolol and 3.5 Ϯ 0.4 nM (n ϭ 10) for carvedilol (Fig. 5B) .
Discussion
Adult rat cardiomyocytes contain ␣ 1 - (Brown et al., 1985; Buxton and Brunton, 1986 ) and ␤ 1 -and ␤ 2 -adrenoceptors (Im et al., 1984; Xiao and Lakatta, 1993 ; for a recent review, see Steinberg, 1999) . We have recently shown that noradrenaline, an ␣ 1 -, ␣ 2 -, and ␤ 1 -adrenoceptor agonist, exerts dual growth-promoting effects on the cardiomyocytes. It increases rate of protein synthesis via ␣ 1 -adrenoceptor stimulation and decreases rate of protein synthesis via ␤ 1 -adrenoceptor stimulation in a cyclic AMP-dependent fashion (Schä fer et al., 2001) . Accordingly, ␤-adrenoceptor antagonists such as propranolol, CGP 20712A, and atenolol increased noradrenaline-induced protein synthesis whereas ␤-adrenoceptor agonists such as isoprenaline, dobutamine, or xamoterol decreased noradrenaline-induced protein synthesis ; Schä fer et al., 2001). Moreover, forskolin and at ASPET Journals on July 9, 2017 jpet.aspetjournals.org dibutyryl cyclic AMP inhibited noradrenaline-induced protein synthesis whereas RpcAMPS, an inhibitor of protein kinase A, could enhance it (Schä fer et al., 2001; Brodde et al., 2001) . On the other hand, the increases in rate of protein synthesis evoked by phenylephrine, a "pure" ␣ 1 -adrenoceptor agonist (at least in concentrations up to 1 M), were not affected by ␤-adrenoceptor antagonists but were inhibited by the ␤-adrenoceptor agonists isoprenaline, dobutamine, and xamoterol .
Carvedilol and bucindolol are nonselective third-generation ␤-blockers (Bristow, 2000) with additional ␣ 1 -adrenoceptor blocking activity. Our radioligand binding data confirm data from the literature (Hershberger et al., 1990; Bristow et al., 1992 ) that carvedilol has a much higher affinity to ␣ 1 -adrenoceptors than bucindolol. We found a ␤ 1 -/␣ 1 -adrenoceptor ratio for carvedilol of 1:2.7 and for bucindolol of 1:43 (cf. Table 1 ).
In the present study, in adult rat ventricular cardiomyocytes, bucindolol-in contrast to carvedilol-exerted a dual effect on noradrenaline-induced increase in rate of protein synthesis. At low, rather selective, ␤-adrenoceptor blocking concentrations (Յ10 nM), bucindolol caused an increase in noradrenaline-induced protein synthesis (similar to what is observed with other ␤-adrenoceptor antagonists; see above) while at higher (now ␣ 1 -adrenoceptor blocking) concentrations, it inhibited noradrenaline-induced increase in rate of protein synthesis. The increase in noradrenaline-induced protein synthesis is due to the ␤-adrenoceptor blocking activity of bucindolol because it completely disappeared when noradrenaline effects were assessed in the presence of 300 nM CGP 20712A or 1 M propranolol; on the other hand, the inhibitory effects of bucindolol on noradrenaline-induced protein synthesis is due to its ␣ 1 -adrenoceptor blocking activity since nearly identical concentration-inhibition curves for bucindolol were obtained inhibiting increase in rate of protein synthesis induced by noradrenaline in the presence of 300 nM CGP 20712A (now acting solely at ␣ 1 -adrenoceptors) or by phenylephrine (a pure ␣ 1 -adrenoceptor agonist).
In contrast to bucindolol, carvedilol did not exert dual effects on noradrenaline-induced increase in rate of protein synthesis; it inhibited noradrenaline-induced increases in rate of protein synthesis in the presence as well as in the absence of 300 nM CGP 20712A with monophasic concentration-inhibition curves and nearly identical K i values (see Fig.  4A ). In addition, similar K i values were also obtained for carvedilol-evoked inhibition of phenylephrine-induced increase in rate of protein synthesis; this supports the view that the inhibitory effect of carvedilol is due to its ␣ 1 -adrenoceptor blocking activity.
It should be noted, however, that bucindolol (1 M) and carvedilol (100 nM and 1 M) caused shifts to the right of the concentration-response curve for noradrenaline-induced increase in rate of protein synthesis that were by far less than could be expected from their affinities for ␣ 1 -adrenoceptors. Thus, at a concentration of 1 M, carvedilol should cause about a 200-fold shift to the right, but the shift observed was only about 20-fold; similarly, bucindolol at a concentration of 1 M should cause about a 25-to 30-fold shift to the right, but the shift observed was only about 10-fold. However, at these rather high concentrations, both carvedilol and bucindolol will inhibit also ␤-adrenoceptors and, by this, induce a shift to the left of the concentration-response curve for noradrenaline. As a consequence, these ␤-adrenoceptor blocking activities will partly counteract the ␣ 1 -adrenoceptor blocking effects of both ␤-adrenoceptor antagonists; this is very likely the reason why the shifts to the right induced by bucindolol and carvedilol are less than could be expected from their ␣ 1 -adrenoceptor blocking activities.
In conclusion, carvedilol and bucindolol differentially affect noradrenaline-induced increase in rate of protein synthesis in adult rat ventricular cardiomyocytes. Bucindolol exerts a dual effect with low (pure ␤-adrenoceptor blocking) concentrations increasing noradrenaline-induced protein synthesis and high (now ␣ 1 -adrenoceptor blocking) concentrations inhibiting noradrenaline-induced increase in rate of protein synthesis. In contrast, carvedilol does not exert such dual effects. It causes no increase but only inhibition of noradrenaline-induced increase in rate of protein synthesis. However, how and/or whether these differential effects of carvedilol and bucindolol on noradrenaline-induced development of a hypertrophic phenotype might contribute to their different effects on mortality in long-term treatment of patients with chronic heart failure (see Introduction) remains to be elucidated.
